Compare SGMO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGMO | NYXH |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.2M | 152.8M |
| IPO Year | 2000 | 2021 |
| Metric | SGMO | NYXH |
|---|---|---|
| Price | $0.26 | $2.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.00 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 7.4M | 53.9K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,567,000.00 | N/A |
| Revenue This Year | $24.46 | $214.32 |
| Revenue Next Year | $193.67 | $124.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 88.60 | N/A |
| 52 Week Low | $0.21 | $2.76 |
| 52 Week High | $0.84 | $8.64 |
| Indicator | SGMO | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 36.49 |
| Support Level | $0.21 | $2.76 |
| Resistance Level | $0.55 | $5.02 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 25.91 | 8.52 |
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.